{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T11:59:02Z","timestamp":1779883142659,"version":"3.53.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T00:00:00Z","timestamp":1569801600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T00:00:00Z","timestamp":1569801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai","doi-asserted-by":"publisher","award":["19ZR1472000"],"award-info":[{"award-number":["19ZR1472000"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s12094-019-02215-7","type":"journal-article","created":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:29:46Z","timestamp":1569889786000},"page":"928-934","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Dynamic monitoring of HER2 amplification in circulating DNA of patients with metastatic colorectal cancer treated with cetuximab"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6803-0594","authenticated-orcid":false,"given":"R.","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,30]]},"reference":[{"key":"2215_CR1","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. 2018;68:394\u2013424.","journal-title":"CA"},{"key":"2215_CR2","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","volume":"29","author":"E Van Cutsem","year":"2011","unstructured":"Van Cutsem E, Kohne CH, Lang I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29:2011\u20139.","journal-title":"J Clin Oncol"},{"key":"2215_CR3","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1200\/JCO.2014.59.4812","volume":"33","author":"E Van Cutsem","year":"2015","unstructured":"Van Cutsem E, Lenz HJ, Kohne CH, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol. 2015;33:692\u2013700.","journal-title":"J Clin Oncol"},{"key":"2215_CR4","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1001\/jama.2017.7105","volume":"317","author":"AP Venook","year":"2017","unstructured":"Venook AP, Niedzwiecki D, Lenz HJ, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA. 2017;317:2392\u2013401.","journal-title":"JAMA"},{"key":"2215_CR5","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/nature11156","volume":"486","author":"S Misale","year":"2012","unstructured":"Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486:532\u20136.","journal-title":"Nature"},{"key":"2215_CR6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.2174\/1568026614666140423121525","volume":"9","author":"F Meriggi","year":"2014","unstructured":"Meriggi F, Vermi W, Bertocchi P, Zaniboni A. The emerging role of NRAS mutations in colorectal cancer patients selected for anti-EGFR therapies. Rev Recent Clin Trials. 2014;9:8\u201312.","journal-title":"Rev Recent Clin Trials"},{"key":"2215_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/nm.2609","volume":"18","author":"C Montagut","year":"2012","unstructured":"Montagut C, Dalmases A, Bellosillo B, et al. Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer. Nat Med. 2012;18:221\u20133.","journal-title":"Nat Med"},{"key":"2215_CR8","doi-asserted-by":"publisher","first-page":"99ra86","DOI":"10.1126\/scitranslmed.3002442","volume":"3","author":"K Yonesaka","year":"2011","unstructured":"Yonesaka K, Zejnullahu K, Okamoto I, et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med. 2011;3:99ra86.","journal-title":"Sci Transl Med"},{"key":"2215_CR9","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","volume":"17","author":"A Sartore-Bianchi","year":"2016","unstructured":"Sartore-Bianchi A, Trusolino L, Martino C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17:738\u201346.","journal-title":"Lancet Oncol"},{"key":"2215_CR10","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S1470-2045(18)30904-5","volume":"20","author":"F Meric-Bernstam","year":"2019","unstructured":"Meric-Bernstam F, Hurwitz H, Raghav KPS, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019;20:518\u201330.","journal-title":"Lancet Oncol"},{"key":"2215_CR11","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nature11219","volume":"486","author":"LA Diaz Jr","year":"2012","unstructured":"Diaz LA Jr, Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486:537\u201340.","journal-title":"Nature"},{"key":"2215_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"2215_CR13","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1038\/modpathol.2015.98","volume":"28","author":"E Valtorta","year":"2015","unstructured":"Valtorta E, Martino C, Sartore-Bianchi A, et al. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Mod Pathol. 2015;28:1481\u201391.","journal-title":"Mod Pathol"},{"key":"2215_CR14","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1093\/annonc\/mdy100","volume":"29","author":"S Siena","year":"2018","unstructured":"Siena S, Sartore-Bianchi A, Marsoni S, et al. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Ann Oncol. 2018;29:1108\u201319.","journal-title":"Ann Oncol"},{"key":"2215_CR15","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/path.4679","volume":"238","author":"SD Richman","year":"2016","unstructured":"Richman SD, Southward K, Chambers P, et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol. 2016;238:562\u201370.","journal-title":"J Pathol"},{"key":"2215_CR16","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1038\/bjc.2014.483","volume":"111","author":"B Ingold Heppner","year":"2014","unstructured":"Ingold Heppner B, Behrens HM, Balschun K, et al. HER2\/neu testing in primary colorectal carcinoma. Br J Cancer. 2014;111:1977\u201384.","journal-title":"Br J Cancer"},{"key":"2215_CR17","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1093\/annonc\/mdu275","volume":"25","author":"E Missiaglia","year":"2014","unstructured":"Missiaglia E, Jacobs B, D\u2019Ario G, et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol. 2014;25:1995\u20132001.","journal-title":"Ann Oncol"},{"key":"2215_CR18","doi-asserted-by":"publisher","first-page":"e0151865","DOI":"10.1371\/journal.pone.0151865","volume":"11","author":"SK Nam","year":"2016","unstructured":"Nam SK, Yun S, Koh J, et al. BRAF, PIK3CA, and HER2 oncogenic alterations according to KRAS mutation status in advanced colorectal cancers with distant metastasis. PLoS One. 2016;11:e0151865.","journal-title":"PLoS One"},{"key":"2215_CR19","doi-asserted-by":"publisher","first-page":"86356","DOI":"10.18632\/oncotarget.21169","volume":"8","author":"ME Salem","year":"2017","unstructured":"Salem ME, Weinberg BA, Xiu J, et al. Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. Oncotarget. 2017;8:86356\u201368.","journal-title":"Oncotarget"},{"key":"2215_CR20","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1158\/1078-0432.CCR-16-1863","volume":"23","author":"F Pietrantonio","year":"2017","unstructured":"Pietrantonio F, Vernieri C, Siravegna G, et al. Heterogeneity of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer. Clin Cancer Res. 2017;23:2414\u201322.","journal-title":"Clin Cancer Res"},{"key":"2215_CR21","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.tranon.2018.11.015","volume":"12","author":"H Zhang","year":"2019","unstructured":"Zhang H, Liu R, Yan C, et al. Advantage of next-generation sequencing in dynamic monitoring of circulating tumor DNA over droplet digital PCR in cetuximab treated colorectal cancer patients. Transl Oncol. 2019;12:426\u201331.","journal-title":"Transl Oncol"},{"key":"2215_CR22","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1002\/cncr.29224","volume":"121","author":"JF Deeken","year":"2015","unstructured":"Deeken JF, Wang H, Subramaniam D, et al. A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies. Cancer. 2015;121:1645\u201353.","journal-title":"Cancer"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-019-02215-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-019-02215-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-019-02215-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T23:21:24Z","timestamp":1601335284000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-019-02215-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,30]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["2215"],"URL":"https:\/\/doi.org\/10.1007\/s12094-019-02215-7","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,30]]},"assertion":[{"value":"1 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors disclose no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Review Board of the Fudan University Shanghai Cancer Center.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All the patients gave written informed consent before starting CTX therapy.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}